 |
|
DIDMOHS: A Proposed Consensus Nomenclature for the Drug-Induced Delayed Multiorgan Hypersensitivity Syndrome
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
While reviewing a manuscript on the "sulfone syndrome," it occurred to us how inconsistent the literature is in referring by name to this rather distinctive syndrome that was initially characterized almost half a century ago.1 Such ambiguity in nomenclature can be harmful since prompt recognition and treatment of this potentially life-threatening but reversible pattern of drug hypersensitivity can be delayed. In addition, terms such as sulfone syndrome and dapsone syndrome are not fully informative because structurally different drugs can produce this hypersensitivity reaction pattern (eg, phenytoin, carbamazepine, phenobarbital, lamotrigine, trimethoprim-sulfamethoxazole, minocycline, procarbazine, allopurinol, or terbinafine). We see this pattern of drug hypersensitivity most often at the inpatient services in our medical center as a result of phenytoin administration. It is not infrequent that the primary care physicians have failed to recognize this syndrome at the time of our evaluation, perhaps reflecting the general medical community's relative lack of familiarity with . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia
Gutierrez-Macias et al.
BMJ 2005;331:623-624.
FULL TEXT
The Drug Hypersensitivity Syndrome: What Is the Pathogenesis?
Sullivan and Shear
Arch Dermatol 2001;137:357-364.
FULL TEXT
|
